纳米姜黄素疗法，一种有前景的调节 COVID-19 患者炎症细胞因子的方法。

Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.

机构信息

Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Student's Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Int Immunopharmacol. 2020 Dec;89(Pt B):107088. doi: 10.1016/j.intimp.2020.107088. Epub 2020 Oct 20.

DOI:10.1016/j.intimp.2020.107088

PMID:33129099

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7574843/

Abstract

BACKGROUND

As an ongoing worldwide health issue, Coronavirus disease 2019 (COVID-19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, which is primarily attributed to the large amount of inflammatory cytokine production. We aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients.

METHOD

Forty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion. Subsequently, COVID-19 patients were divided into two groups: 20 patients receiving Nano-curcumin and 20 patients as the placebo group. The mRNA expression and cytokine secretion levels of IL-1β, IL-6, TNF-α and IL-18 were assessed by Real-time PCR and ELISA, respectively.

RESULT

Our primary results indicated that the mRNA expression and cytokine secretion of IL-1β, IL-6, TNF-α, and IL-18 were increased significantly in COVID-19 patients compared with healthy control group. After treatment with Nano-curcumin, a significant decrease in IL-6 expression and secretion in serum and in supernatant (P = 0.0003, 0.0038, and 0.0001, respectively) and IL-1β gene expression and secretion level in serum and supernatant (P = 0.0017, 0.0082, and 0.0041, respectively) was observed. However, IL-18 mRNA expression and TNF-α concentration were not influenced by Nano-curcumin.

CONCLUSION

Nano-curcumin, as an anti-inflammatory herbal based agent, may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may cause an improvement in clinical manifestation and overall recovery.

摘要

背景

作为当前全球范围内的健康问题，2019 年冠状病毒病（COVID-19）已导致严重并发症，包括肺炎、急性呼吸窘迫综合征（ARDS）和多器官衰竭。然而，对于这种疾病还没有决定性的治疗方法，主要原因是大量炎症细胞因子的产生。我们旨在确定 Nano-curcumin 对 COVID-19 患者炎症细胞因子调节的影响。

方法

招募了 40 名 COVID-19 患者和 40 名健康对照者，评估其炎症细胞因子的表达和分泌情况。随后，将 COVID-19 患者分为两组：20 名患者接受 Nano-curcumin 治疗，20 名患者作为安慰剂组。通过 Real-time PCR 和 ELISA 分别评估 IL-1β、IL-6、TNF-α 和 IL-18 的 mRNA 表达和细胞因子分泌水平。

结果

我们的主要结果表明，与健康对照组相比，COVID-19 患者的 IL-1β、IL-6、TNF-α 和 IL-18 的 mRNA 表达和细胞因子分泌显著增加。用 Nano-curcumin 治疗后，血清和上清液中 IL-6 的表达和分泌明显下降（P 值分别为 0.0003、0.0038 和 0.0001），血清和上清液中 IL-1β 基因表达和分泌水平也明显下降（P 值分别为 0.0017、0.0082 和 0.0041）。然而，Nano-curcumin 对 IL-18mRNA 表达和 TNF-α 浓度没有影响。